Cargando…

Impact of SARS-CoV-2 envelope protein mutations on the pathogenicity of Omicron XBB

Detalles Bibliográficos
Autores principales:	Wang, Yi, Pan, Xiaoyan, Ji, Hongying, Zuo, Xiaoli, Xiao, Geng-Fu, Li, Jia, Zhang, Lei-Ke, Xia, Bingqing, Gao, Zhaobing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382526/ https://www.ncbi.nlm.nih.gov/pubmed/37507399 http://dx.doi.org/10.1038/s41421-023-00575-7

Ejemplares similares

Why is the SARS-CoV-2 Omicron variant milder?
por: Xia, Bingqing, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant
por: Yamasoba, Daichi, et al.
Publicado: (2023)

SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects – correspondence
por: Channabasappa, Nikhil K., et al.
Publicado: (2023)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
por: Uriu, Keiya, et al.
Publicado: (2023)

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023)

Bivalent mRNA vaccine-elicited SARS-CoV-2 specific T cells recognise the omicron XBB sublineage
por: Traut, Caroline C, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
por: Mykytyn, Anna Z, et al.
Publicado: (2023)

Coding-Complete Genome Sequences of 40 SARS-CoV-2 Omicron XBB, XBB.1, and XBB.2 Sublineage Strains in Bangladesh
por: Habib, Mohammad Tanbir, et al.
Publicado: (2023)

A commentary on ‘Re-emergence of SARS-CoV-2 Omicron subvariant XBB.1.5: present status, treatment, and future outlook – 2023’
por: Chiu, Si-Un Frank, et al.
Publicado: (2023)

Enhanced channel activity by PI(4,5)P(2) ignites MLKL-related pathogenic processes
por: Xia, Bingqing, et al.
Publicado: (2022)

Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage
por: Nehlmeier, Inga, et al.
Publicado: (2023)

Coding-complete genomes of XBB.1.16, XBB.2.3, FL.4 (alias of XBB.1.9.1.4), and XBB.3 of SARS-CoV-2 Omicron isolated from Bangladesh
por: Rahman, Saikt, et al.
Publicado: (2023)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

Recent update on XBB.1.5 emerging novel mutation of COVID-19
por: Amin, Ruhul, et al.
Publicado: (2023)

Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
por: Tay, Matthew Zirui, et al.
Publicado: (2023)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

XBB.1.5 an emerging threat: correspondence
por: Mohanty, Aroop, et al.
Publicado: (2023)

Integrative Genome-Based Survey of the SARS-CoV-2 Omicron XBB.1.16 Variant
por: Scarpa, Fabio, et al.
Publicado: (2023)

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants
por: Tamura, Tomokazu, et al.
Publicado: (2023)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
por: Hoffmann, Markus, et al.
Publicado: (2023)

What to know about Omicron XBB.1.5
por: Vogel, Lauren
Publicado: (2023)

Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
por: Wang, Xun, et al.
Publicado: (2023)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant
por: Zhang, Wei, et al.
Publicado: (2022)

Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
por: Parums, Dinah V.
Publicado: (2023)

Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB(*) infections
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients
por: Affeldt, Patrick, et al.
Publicado: (2023)

Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies
por: Chen, Shiqi, et al.
Publicado: (2023)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
por: Zuo, Fanglei, et al.
Publicado: (2023)

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
por: He, Cai, et al.
Publicado: (2023)

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5
por: Yue, Can, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3n0n312foiq74q6hbig9r2g8fb